MV 130

Drug Profile

MV 130

Alternative Names: Bactek; BACTEK-MV130; Bactek-O; Bacterial-polivalent-vaccine-Inmunotek; MV-130

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inmunotek
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bacterial infections; Bronchospasm

Most Recent Events

  • 17 Jul 2018 Health Research Council of New Zealand and Inmunotek plans a pilot phase II trial for Bronchiectasis in New Zealand (Sublingual, Spray) in September 2018 (ACTRN12618001171202p)
  • 18 Feb 2016 MV 130 is still in phase III trial for Bacterial infections (Prevention) in Spain (Sublingual) (NCT01842360)
  • 13 Dec 2012 Phase-III clinical trials in Bacterial infections (Prevention) in Spain (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top